Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

Report Scope

This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs.

The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies.

The growing number of individuals with leukemia is the main reason for the market's growth and the development of more effective drugs.

Report Includes

49 data tables and 44 additional tables

An overview of the current and future global markets for drugs and diagnostics for hematological disorders

Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029

Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region

Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors

A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis

Review of technological developments, product introductions, and other recent industry activity of the major players

Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices

An analysis of recent patents

A look at the competitive landscape, including companies’ market shares, M&A activity and venture funding

Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Companies Mentioned

ABBOTT
AMGEN INC.
BIO-RAD LABORATORIES INC.
BRISTOL MYERS SQUIBB CO.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
NOVARTIS AG
SANOFI
SYSMEX CORP.
TAKEDA PHARMACEUTICAL CO. LTD.